Home / 2022 / June / 14

Daily Archives: June 14, 2022

Exxact Corporation Releases New GRAID SupremeRAID™ Powered NVMeoF Storage Solution for AI and HPC Workloads

Exxact now offers the GRAID SupremeRAID™ NVMeoF storage server designed to deliver lightning-fast SSD performance in AI-accelerated compute, AFA, and HPC applications.

Exxact Corporation Releases New GRAID SupremeRAID™ Powered NVMeoF Storage Solution for AI and HPC

Exxact Corporation Releases New GRAID SupremeRAID™ Powered NVMeoF Storage Solution for AI and HPC

SANTA CLARA, Calif., June 14, 2022 (GLOBE NEWSWIRE) —  Exxact Corporation, a North America-based leading provider of high-performance computing (HPC), artificial intelligence (AI), and data center solutions, announced that it is now offering NVMeoF storage solutions featuring GRAID SupremeRAID™. This new line of GPU-accelerated RAID uses revolutionary AI to eliminate the traditional RAID bottleneck in mass storage, enabling maximum SSD performance for high-intensity workloads.

GRAID SupremeRAID™ enables superior NVMe/NVMeoF, SAS, and SATA performance in AI-accelerated compute, AFA, and HPC applications while increasing scalability, improving flexibility, and lowering TCO. Designed for both Linux and Windows operating systems, GRAID SupremeRAID™ supports RAID levels 0/1/10/5/6/JBOD while the core software license supports up to 32 native NVMe drives.

“By partnering with GRAID, Exxact can help customers unlock the full potential of NVMe SSD performance by leveraging powerful computing and software capabilities to achieve significant performance gain over traditional RAID without requiring any memory caching,” said Andrew Nelson, Vice President of Technology at Exxact Corporation. 

“We are pleased to partner with Exxact to offer flexible, easy-to-configure IT infrastructure solutions that drive technology forward while delivering our customers an incredible competitive advantage in the market,” said Leander Yu, CEO and President of GRAID Technology.

Learn more about Exxact Corporation’s GRAID offerings here: https://www.exxactcorp.com/category/NVMe-oF-Storage-Solutions

About Exxact

Founded in 1992, Exxact is an ISO-certified provider of innovative computing appliances that include workstation, server, cluster, and storage products developed for life sciences, HPC, big data, and cloud applications. With a full range of engineering and logistics services, including consultancy, validation, implementation, and support, Exxact enables its customers to solve complex computing challenges and improve resource utilization to maintain a competitive edge. Visit Exxact Corporation at www.exxactcorp.com.


GRAID Technology is headquartered in Silicon Valley, California with an office in Ontario, CA, and an R&D center in Taipei, Taiwan. Named one of the Ten Hottest Data Storage Startups of 2021 by CRN, GRAID SupremeRAID™ performance is breaking world records as the first NVMe and NVMeoF RAID card to unlock the full potential of your SSD performance: a single SupremeRAID™ card delivers 19 million IOPS and 110GB/s of throughput. For more information on GRAID Technology, visit graidtech.com or connect with us on Twitter or LinkedIn.

Additional Resources

GRAID Media Contact:
Andrea Eaken (GRAID PR/Marketing)

Related Images

Image 1: Exxact Corporation Releases New GRAID SupremeRAID™ Powered NVMeoF Storage Solution for AI and HPC

This content was issued through the press release distribution service at Newswire.com.


A Sustainable Year: CNH Industrial presents key highlights

A Sustainable Year 2021

A Sustainable Year 2021, from CNH Industrial

CNH Industrial has published the companion guide to its 2021 Sustainability Report, A Sustainable Year. The publication is also available as an interactive online magazine. Visit publications.cnhindustrial.com/a-sustainable-year-2021 to learn more about how the Company and its people proactively work to make the world a better place.

London, June 14, 2022

CNH Industrial (NYSE: CNHI / MI: CNHI) has redoubled its commitment to a more sustainable future, as evidenced by the sixth edition of A Sustainable Year which highlights a selection of sustainability initiatives accomplished in 2021.

It complements the earlier publication of the 2021 Sustainability Report, providing a reader-friendly snapshot of the Company’s major social, economic, and environmental activities as well as its strategic sustainability targets.

A Sustainable Year showcases some of the projects and initiatives that are enabling CNH Industrial to pursue its sustainability strategy. Highlights include CASE Construction Equipment’s beach care project to tackle plastic waste and raise awareness, and the Company’s program to install solar panels on the roofs of all manufacturing plants by 2030. It also details the New Holland brand’s e-Source, a new plug-in system which transforms mechanical energy generated by a tractor into electricity to power implements, consequently reducing carbon emissions, improving safety standards, and saving fuel.

Furthermore, the publication provides updates on how the Company is engaged with its people and communities at large, promoting Diversity and Inclusion initiatives and supporting its customers on their own sustainability journeys.

These stories are testament to CNH Industrial’s leading role in corporate sustainability. The Company continues to be acknowledged for its commitment, including 11 consecutive years of being named as an Industry Top Scorer in the Dow Jones Sustainability World and Europe Indexes.

Download the latest edition of A Sustainable Year in PDF HERE
Peruse the interactive version HERE

CNH Industrial (NYSE: CNHI / MI: CNHI) is a world-class equipment and services company. Driven by its purpose of Breaking New Ground, which centers on Innovation, Sustainability and Productivity, the Company provides the strategic direction, R&D capabilities, and investments that enable the success of its global and regional Brands. Globally, Case IH and New Holland Agriculture supply 360° agriculture applications from machines to implements and the digital technologies that enhance them; and CASE and New Holland Construction Equipment deliver a full lineup of construction products that make the industry more productive. The Company’s regionally focused Brands include: STEYR, for agricultural tractors; Raven, a leader in digital agriculture, precision technology and the development of autonomous systems; Flexi-Coil, specializing in tillage and seeding systems; Miller, manufacturing application equipment; Kongskilde, providing tillage, seeding and hay & forage implements; and Eurocomach, producing a wide range of mini and midi excavators for the construction sector, including electric solutions. Across a history spanning over two centuries, CNH Industrial has always been a pioneer in its sectors and continues to passionately innovate and drive customer efficiency and success. As a truly global company, CNH Industrial’s 37,000+ employees form part of a diverse and inclusive workplace, focused on empowering customers to grow, and build, a better world.

For more information and the latest financial and sustainability reports visit: cnhindustrial.com

For news from CNH Industrial and its Brands visit: media.cnhindustrial.com

Media contacts:

Rebecca Fabian Anna Angelini
North America United Kingdom
Tel. +1 312 515 2249 Tel. +44 (0)7725 826 007



Epiq Celebrates 15 Years in the eDiscovery Managed Services Business with the Launch of Epiq Choice

The new technology offering gives clients unprecedented flexibility in managing projects

NEW YORK, June 14, 2022 (GLOBE NEWSWIRE) — Epiq, a technology-enabled services leader to global corporate legal departments and law firms, announced today the launch of Epiq Choice and a corresponding milestone: celebrating 15 years since pioneering eDiscovery managed services. Senior Vice President of eDiscovery Services, Scott Berger, who won a Lifetime Achievement award at this year’s Leaders in Tech Law Awards during Legalweek NY, led a team that originally conceived of and launched eDiscovery managed services in 2007. Their goal was to take a concept known to other industries and apply it to the legal technology and support industry. It was designed to combat the unpredictability of price, service quality, and technology utilization that was prevalent in legal at the time, and the effort has led to major changes in the way legal does business. Epiq Choice is the next step in that journey of providing flexibility and value to clients.

Epiq Choice is in keeping with Epiq’s reputation as a trailblazer and leading provider in eDiscovery. With it, leaders in corporations and law firms can take advantage of multiple eDiscovery tools in one place with easy access via the Epiq Service Cloud, and with a predictable monthly fee. Epiq Choice provides clients with the existing eDiscovery tools they are accustomed to, along with the ability to explore new technologies, without having to make specific commitments or investments to exact tools and volumes.

“For many of our clients, Epiq Choice is the answer to the unknown,” said Scott Berger. “The tools and technologies within our industry are rapidly evolving, and in some cases, a new tool might be the perfect fit for a specific matter. Epiq Choice allows clients to benefit from our own investments in platforms and training without having to shoulder the risk themselves. Our history and spirit of innovation made us The Leader in eDiscovery Managed ServicesTM, and Epiq Choice is the next evolution in the journey.”

The eDiscovery platforms currently available via Epiq Choice include Epiq Discovery, NUIX, Reveal, Relativity, and RelativityOne. Epiq Choice is fully integrated into the Epiq Service Cloud, which provides a modernized digital experience for working with Epiq, along with centralized and secure single-sign-on capabilities for a law firm or legal department’s entire tech-stack via Epiq Access.

The innovative spirit that drives Epiq’s eDiscovery Managed Services team and has led to its growth was validated earlier this year by the Leaders in Legal Tech Law Awards Lifetime Achievement recognition.

“It is appropriate that the award for Scott came in the same year that Epiq commemorates the 15th anniversary of our managed service offering and launches this exciting new technology,” said Roger Pilc, president and general manager for Epiq’s Legal Solutions business. “Under his leadership, the Epiq team has become dominant in the space, growing from fewer than 20 people to more than 250 professionals dedicated solely to the managed services program, making it the largest and most experienced pool of eDiscovery experts available. The group partners with more than 100 clients and leads the industry in leveraging innovation such as AI model libraries on their behalf. We could not be more proud of all that this team has accomplished.”

To learn more about how Epiq’s eDiscovery Managed Services, visit us here.

About Epiq
Epiq, a global technology-enabled services leader to the legal industry and corporations, takes on large-scale, increasingly complex tasks for corporate counsel, law firms and business professionals with efficiency, clarity and confidence. Clients rely on Epiq to streamline the administration and transformation of business and legal operations, class action and mass tort, court reporting, eDiscovery, regulatory, compliance, restructuring and bankruptcy matters. Epiq subject-matter experts and technologies create efficiency through expertise and deliver confidence to high-performing clients around the world. Learn more at www.epiqglobal.com.

Press Contact
Candice Russell
+1 203 461 5852

Cambridge Epigenetix Names Peter Fromen as Chief Executive Officer

Genomics Veteran to Lead Company Which Has a Commercial-Ready Novel Technology Platform that Can Realize the Largely Untapped Contribution of Epigenetics to Human Health

Cambridge Epigenetix Names Peter Fromen as Chief Executive Officer

Genomics Veteran to Lead Company Which Has a Commercial-Ready Novel Technology Platform that Can Realize the Largely Untapped Contribution of Epigenetics to Human Health

CAMBRIDGE, United Kingdom, June 14, 2022 (GLOBE NEWSWIRE) — Cambridge Epigenetix (CEGX), a life sciences tools and technology company which is revolutionizing genome sequencing, today announced the appointment of Peter J. Fromen as Chief Executive Officer effective July 18, 2022. Gail Marcus who has been acting Chief Executive Officer since 2020 will continue as Chair of the Board.

Professor Sir Shankar Balasubramanian FRS, co-founder of Cambridge Epigenetix, said, “We welcome Peter and his vast industry experience and valuable relationships to lead Cambridge Epigenetix at this critical juncture. The founders, Gail and the entire Board are delighted to have Peter’s leadership as we seek to grow the company into its full potential.”

Mr. Fromen joins the company from PacBio (NASDAQ: PACB) where he served as Chief Commercial Officer (CCO), based in London. During his tenure, he transformed the commercial organization and led the team to achieve record levels of sales, growing revenues by 65% and more than doubling the company’s installed base of sequencers.

“Peter brings global leadership and broad commercial expertise leading key functions in product marketing, product management, market development, sales, service, and support. His record of building, growing, and retaining world-class teams is particularly important to us as we prepare for the future,” shared Gail Marcus. “We are confident Peter and his leadership style will enhance our innovation-centric culture which- is built on integrity, humility and diversity.”

Prior to PacBio, Mr. Fromen worked at Illumina where he held numerous leadership positions across the finance and commercial organizations including investor relations, product marketing, market development, and enterprise sales. He built the Company’s first investor relations and market development functions and had a leading role in launching the Company’s HiSeq X Ten Sequencing System which delivered the first $1000 human whole genome. Notably, while serving as the company’s Global Vice President of Population Genomics and Precision Health, Mr. Fromen oversaw Illumina’s partnership with Genomics England and the National Health System (NHS) to execute the 100,000 Genomes Project which subsequently led to the commissioning of whole genome sequencing in the NHS for rare disease and certain cancers.

“The founders of Cambridge Epigenetix had the foresight and wisdom to envision the potential of epigenetics before anyone else, attracting an industry leading Board and group of investors. This exceptional team has developed one of the most exciting technology platforms I have seen in my career. It has the potential to dramatically reduce the cost of capturing novel epigenetic information while preserving its genetic context, all in a single sequencing workflow,” said Peter Fromen. “I am deeply excited to join Cambridge Epigenetix and lead the company to its next stage of growth, empowering customers to realize the full contribution of epigenetics to human health.”

About Cambridge Epigenetix

Cambridge Epigenetix, a life sciences tools and technology company, is revolutionizing sequencing by delivering new dimensions of information from DNA to identify and treat disease earlier, harnessing the potential to transform life sciences and medicine. The commercial-stage company’s platform provides more information with greater efficiency at higher quality and lower cost than standard next generation sequencing technologies. Easily integrating into existing sequencers, the company’s products allow the user to simultaneously see genetic and epigenetic information in a single workflow. This information can be used to detect, diagnose, treat, and understand disease. Based in Cambridge, UK, amongst the Company’s founders is a pioneer in DNA sequencing, intent on leading the next great leap forward in genomics. To learn more, please visit https://cambridge-epigenetix.com/

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/71ea248c-5c35-478c-8817-a67392de430a

Business Contact

Media Contact

Definitive Healthcare launches Monocl ExpertInsight 2.0 and ExpertGO mobile app

Medical affairs teams can now access the scientific activities of nearly 13 million experts globally across all therapeutic areas in a single platform

FRAMINGHAM, Mass., June 14, 2022 (GLOBE NEWSWIRE) — Definitive Healthcare (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced the general availability of Monocl ExpertInsight 2.0, the next generation of the company’s expert identification product, and a new mobile app, Monocl ExpertGO. These new offerings give medical affairs professionals access to nearly 13 million expert profiles globally so they can more quickly identify and engage the right scientific experts to provide critical insights that can accelerate the drug development process.

Monocl ExpertInsight 2.0 provides an optimized user experience that helps medical affairs teams increase productivity, streamline workflows and develop more informed medical strategies. Monocl ExpertInsight 2.0 equips medical affairs teams with:

  • Live filters that provide an overview of scientific activity with real-time updates and filters by expert and/or therapeutic area
  • Advanced search functionality to identify experts more easily in specific disease areas
  • Dynamic key opinion leader (KOL) mapping, which displays the location of experts in granular detail down to the city level

Existing clients will get access to these new features at no additional cost as part of their existing Monocl ExpertInsight subscription.

“We’re passionate about helping medical affairs teams find the right experts who can help accelerate time to market for a new drug or medical device,” said Robert Musslewhite, president of Definitive Healthcare. “With today’s release, our customers now have access to nearly 13 million key opinion leaders, and they can get the insights they need on those leaders from any location with our new ExpertGO mobile app.”

The new ExpertGO mobile app gives field medical leaders and medical science liaisons (MSLs) access to the latest intelligence, scientific activity and collaborator insights on experts around the globe. The ability to access these insights when and where needed is particularly valuable for MSLs, most of whom spend the majority of their time outside of the office, where they are visiting with experts in person.

ExpertGO will be available to download on Apple and Android devices in late June at no additional cost to existing ExpertInsight customers.

As part of this latest release, Definitive Healthcare also added Brazilian expert data to the Monocl ExpertInsight database to help life sciences teams gain a deeper understanding of the South American market. The new data covers intelligence on Brazilian healthcare professionals’ (HCPs) location and specialty, using claims data.

About Definitive Healthcare

At Definitive Healthcare, our passion is to transform data, analytics and expertise into healthcare commercial intelligence. We help clients uncover the right markets, opportunities and people, so they can shape tomorrow’s healthcare industry. Our SaaS platform creates new paths to commercial success in the healthcare market, so companies can identify where to go next. Learn more at definitivehc.com.

Investor Relations Contact:
Brian Denyeau
ICR for Definitive Healthcare

Media Contacts:
Danielle Johns

Highwire PR

Impulse Dynamics Announces First International Implants of the Optimizer Smart Mini System in Italy

MARLTON, N.J., June 14, 2022 (GLOBE NEWSWIRE) — Impulse Dynamics, a commercial-stage medical device company focused on delivering our CCM therapy to people with heart failure, announced that the first implants in Europe for the newly launched Optimizer® Smart Mini device were recently completed in Italy. The company announced the launch of the new technology on April 29, 2022, and the first U.S. implants on May 10, 2022.

Dr. Stefano Guarracini, Head of Cardiology at the Synergo Casa di Cura Pierangeli Hospital in Pescara, Italy, described his experience with CCM therapy and his outlook for the Optimizer Smart Mini system after the first implant. “Starting in 2019, we had the opportunity to implant Optimizer devices in several patients with heart failure. We believe in the technology and consider CCM therapy to be the only option for many patients suffering from heart failure. We are excited now to be affiliated with the first European institution to have implanted the new Optimizer Smart Mini device and look forward to the simple but more advanced patient management experiences during implants and follow-ups going forward.”

Dr. Giovani Bisignani, with the Ospedale di Castrovillari, who completed his first implant almost simultaneously in the southern Italian province of Cosenza, said, “CCM therapy is a powerful weapon against heart failure. The cutting-edge technology of the new Optimizer Smart Mini along with its smaller, physiological shape allowed us to achieve efficient implantation and initiation of CCM therapy in even less time.”

In March 2022, the company announced that its quality management system received certification under the new European Union Medical Device Regulation. We believe that the launch of the Optimizer Smart Mini system is an example of the importance of a global infrastructure to support ongoing technology innovation and access. The new components of the Optimizer Smart Mini system are equally important across international markets, including a rechargeable battery with a 20-year life and new internal technology with improved programming and potential for remote monitoring in a smaller design to make the implant procedure easier for patients and physicians.

“The pace of this international rollout is a reflection of our commitment to delivering innovation that is relevant to patients worldwide,” said Mateusz Zelewski, MD, Impulse Dynamics’ Vice President International, “It is exciting to see how quickly we can increase access to new and better technology that offers hope for more patients living with heart failure.”

The Optimizer Smart Mini delivers CCM therapy, which consists of electric pulses applied to the heart between heartbeats and serves to enhance the performance of cardiac muscular contraction, making the heart work more efficiently without increasing the heart rate or the oxygen consumption of the cardiac muscle. CCM therapy is currently indicated in Europe to reduce hospitalizations and improve physical exercise tolerance, quality of life, and functional status for a large population of patients with systolic heart failure who remain symptomatic despite guideline-directed medical therapy.

To date, CCM therapy has already been used to treat over 7,000 patients worldwide and is available in 44 countries across the globe. The therapy has been studied in almost 2,000 patients and has appeared in more than 100 peer-reviewed journal articles. Ongoing studies are also underway to examine the safety and efficacy of CCM for patients suffering from heart failure with a left ventricular ejection fraction between 40 – 60%.

About Impulse Dynamics

Impulse Dynamics is dedicated to helping healthcare providers enhance the lives of people with heart failure by transforming how the condition is treated. The company is focused on delivering its proprietary CCM therapy, which is delivered by the company’s Optimizer Smart device, the CE-marked, and FDA-approved treatment verified to improve the quality of life for heart failure patients. CCM therapy is a safe, effective, and minimally invasive treatment option for many heart failure patients who otherwise have few effective options available to them.[1] To learn more, visit www.ImpulseDynamics.com, or follow the company on LinkedIn, Twitter, and Facebook.

Forward-looking Statements

This press release contains forward-looking statements. All statements other than statements of historical facts contained in this press release are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as ‘‘may,’’ ‘‘will,’’ ‘‘should,’’ ‘‘expect,’’ ‘‘plan,’’ ‘‘anticipate,’’ ‘‘could,’’ ‘‘intend,’’ ‘‘target,’’ ‘‘project,’’ ‘‘contemplate,’’ ‘‘believe,’’ ‘‘estimate,’’ ‘‘predict,’’ ‘‘potential’’ or ‘‘continue’’ or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements include, but are not limited to, statements concerning potential benefits of CCM therapy, and the absence of risks associated therewith; the ability for CCM therapy and our products to fill a significant unmet medical need for patients with heart failure; and the short-term and long-term benefits of the Optimizer Smart Mini and CCM therapy in patients with heart failure, as well as to the physicians treating those patients. These forward-looking statements are based on management’s current expectations and involve known and unknown risks and uncertainties that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Other important factors that could cause actual results, performance or achievements to differ materially from those contemplated in this press release include, without limitation: the company’s future research and development costs, capital requirements and the company’s needs for additional financing; commercial success and market acceptance of CCM therapy; the company’s ability to achieve and maintain adequate levels of coverage or reimbursement for Optimizer Smart and Optimizer Smart Mini systems or any future products the company may seek to commercialize; competitive companies and technologies in the industry; the company’s ability to expand its indications and develop and commercialize additional products and enhancements to its current products; the company’s business model and strategic plans for its products, technologies and business, including its implementation thereof; the company’s ability to expand, manage and maintain its direct sales and marketing organization; the company’s ability to commercialize or obtain regulatory approvals for CCM therapy and its products, or the effect of delays in commercializing or obtaining regulatory approvals; FDA or other U.S. or foreign regulatory actions affecting us or the healthcare industry generally, including healthcare reform measures in the United States and international markets; the timing or likelihood of regulatory filings and approvals; and the company’s ability to establish and maintain intellectual property protection for CCM therapy and products or avoid claims of infringement. The company does not undertake any obligation to update forward-looking statements and expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein. These forward-looking statements should not be relied upon as representing the company’s views as of any date subsequent to the date of this press release.

[1] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5494150/


Rex Richmond, Director (Media Relations)
Impulse Dynamics

Harriss Currie, CFO (Investor Relations)
Impulse Dynamics

Ian Segal, Public Relations
Impulse Dynamics

10 Most Instagrammed Light Artworks at Vivid Sydney 2022

Yarrkalpa – Hunting Ground 2021, Sydney Opera House

Yarrkalpa – Hunting Ground 2021, Sydney Opera House

SYDNEY, June 14, 2022 (GLOBE NEWSWIRE) — It’s official. The most Instagrammed light artwork at Vivid Sydney 2022 is the Sydney Opera House Lighting of the Sails’ new digital artwork, Yarrkalpa — Hunting Ground 2021 by the Martu Artists and creative technologists Curiious.

Vivid Sydney, the annual festival of Light, Music and Ideas is one of the most Insta-worthy events in the world, transforming Sydney’s central business district (CBD) into a fusion of creativity, innovation and technology until Saturday 18 June. The 2022 festival features more than 50 light installations and projection artworks from 62 light collaborators and 114 artists from five countries, along the longest continuous Light Walk ever at 8km.

Other frontrunners for the most shared artwork on Instagram include Convergence — the largest laser installation ever seen at Vivid Sydney in the disused railway tunnel at the Goods Line; the first-ever floating Light Walk at Walsh Bay, Ephemeral Oceanic; the mesmerising giant globe Gravitational Grid in First Fleet Park, The Rocks; and Ken Done’s For Sydney With Love projection on the façade of Customs House.

Minister for Enterprise, Investment, Trade and Tourism Stuart Ayres said there was a 67 per cent increase overall in social shares using #vividsydney from 2019.

“It has already been a record-breaking year for Vivid Sydney, with the festival welcoming the largest-ever audiences over the opening weekend and bumper attendance over the Queen’s birthday long weekend,” Ayres said.

“Visitors are also sharing their experiences at Vivid Sydney more than ever across their social channels, with First Nations digital artwork, Yarrkalpa — Hunting Ground 2021, the most photographed and shared. I encourage everyone to keep posting and sharing their personal experiences right up until the lights are turned off on 18 June.”

Festival Director Gill Minervini said the variety of light artworks and projections on the Light Walk this year ensured there was a real cross section of artistic highlights from across the Light program.

“I really enjoy watching what captivates our audiences on the Light Walk and I’m thrilled to see so many different genres of Light art appealing to everyone who experiences the festival. It’s great to see some of my personal favourites including For Sydney With Love by Ken Done and Spinifex Group; the interactive projection Vivid Reflections on the Central Station clocktower by The Electric Canvas; and the glorious reflective artwork Temple by Leila Jeffreys receiving so much love on social media.”

In 2022, 11 Sydney CBD locations are ignited, two of which are new, with Circular Quay, Sydney CBD, The Rocks, Walsh Bay, Barangaroo, Darling Harbour, Darling Square, Darling Quarter, The Goods Line, Central Train Station, Luna Park and Taronga Zoo, all coming to life with a mesmerising kaleidoscope of light artworks to wow visitors and locals alike.

Staged over 23 nights, the festival will deliver mesmerising art displays, 3D light projections, uplifting live music performances and deep-dive discussions from the world’s brightest minds.

The full list of the 10 most Instagrammed light artworks at Vivid Sydney 2022 are:

  1.  Yarrkalpa — Hunting Ground 2021, Sydney Opera House Lighting of the Sails
  2.  Convergence
  3.  Ephemeral Oceanic
  4.  Gravitational Grid
  5.  For Sydney With Love
  6.  Sydney Infinity
  7.  Macula
  8.  Temple 
  9.  Vivid Reflections
  10.  Paramount+ Drone Show

*Source:  The most Instagrammed list was compiled by Destination NSW based on assets uploaded against #vividsydney on Instagram. 

For more information on Vivid Sydney including the full program and to purchase tickets, go to www.vividsydney.com. Get social using @vividsydney #vividsydney

Media Contact:
Wayne Mitcham
Destination NSW

Related Images

Image 1: Yarrkalpa – Hunting Ground 2021, Sydney Opera House

Photo credit: Destination NSW

Image 2: Convergence by artist Mandylights

Photo credit: Destination NSW

Image 3: Ephemeral Oceanic by artist Atelier Sisu

Photo credit: Destination NSW

Image 4: Gravitational Grid, artist Sreelize Studio

Photo credit: Destination NSW

Image 5: For Sydney with Love – artist, Ken Done

Photo credit: Destination NSW

This content was issued through the press release distribution service at Newswire.com.